Oracle Gains ‘Outperform’ Rating as Analysts See AI Boost, Delta Air Lines Soars on Earnings
Several major companies reported earnings and received analyst updates today, leading to significant market movement as investors assess the current economic landscape.
Baird initiated coverage of Oracle with an “outperform” rating, setting a price target of $365 per share, which represents a potential 27% increase from yesterday’s closing price. Analyst Rob Oliver cited the company’s strong position to benefit from increased spending on artificial intelligence infrastructure and the integration of AI with data and applications. “We view ORCL as very well positioned to benefit from the accelerating spend on AI infrastructure, and the convergence of AI, data and use-cases that will emerge from the move from training to inference,” Oliver wrote. This comes despite a recent pullback in Oracle shares following reports of tighter margins in its cloud business; the broader tech sector is closely watching how companies will navigate the costs of implementing AI technologies.
Delta Air Lines shares rose more than 5% after the company exceeded analyst expectations with its third-quarter earnings, reporting adjusted earnings of $1.71 per share on revenue of $15.2 billion. These results signal continued strength in the travel sector, despite ongoing economic uncertainties. Investors are paying close attention to airline performance as a gauge of consumer spending. You can find more information about airline industry trends at the International Air Transport Association.
In the biopharmaceutical sector, Akero Therapeutics saw its stock rally nearly 20% after announcing it would be acquired by Novo Nordisk for $4.7 billion in cash. The acquisition focuses on Akero’s drug efruxifermin (EFX), currently in phase 3 trials for metabolic dysfunction-associated steatohepatitis (MASH). Novo Nordisk CEO Mike Doustdar stated, “If approved, we believe it could become a cornerstone therapy…to tackle one of the fastest-growing metabolic diseases of our time.” This acquisition underscores the growing investment in treatments for metabolic diseases, a field gaining prominence with the rise of drugs like Wegovy. For a deeper understanding of MASH, see the National Institute of Diabetes and Digestive and Kidney Diseases.
PepsiCo also reported third-quarter results that beat analyst expectations, with adjusted earnings of $2.29 per share on revenue of $23.94 billion. Stock futures were little changed after 6 p.m. ET, suggesting a cautious outlook as investors await further economic data.
